Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

In the ReSPonD trial we aimed to assess whether ameliorating the cholinergic deficit with an acetylcholinesterase inhibitor rivastigmine would reduce gait variability